FHG is a nationally recognized expert in modeling the financial impact of lung nodules and lung cancer screening programs.
Our financial models quantify the reimbursement and cost implications of managing lung cancer and nodule patients across a range of screening strategies, helping healthcare organizations manage and treat patients within these programs.
Emerging technologies, particularly Artificial Intelligence (AI), are redefining nodule and lung cancer detection and treatment. AI now plays a transformative role in better identifying high-risk patients, streamlining diagnostic workflows, and influencing clinical decisions throughout the lung cancer care continuum.
In 2024, FHG was honored to support the financial modeling for a landmark study evaluating AI’s use in reading imaging reports and triaging indeterminate pulmonary nodules. This work demonstrated how AI was used to read imaging reports, to detect, and effectively triage indeterminate pulmonary nodules without adding additional personnel, saving lives.
Published in the Annals of Thoracic Surgery (2024;118:712–9), the paper titled, “Artificial Intelligence: Can It Save Lives, Hospitals, and Lung Screening”, © 2024 The Society of Thoracic Surgeons, published by Elsevier Inc., highlights the impact of this innovative approach.
FHG is proud to partner with lung cancer healthcare professionals nationwide, leveraging our deep financial expertise to expand early detection, increase screening rates, and prioritize the evaluation and treatment of incidentally detected nodules (IPN). As AI transforms clinical care, FHG is ready to quantify its financial impact and accelerate value-driven strategies in lung cancer and nodule detection programs for the treatment of these patients worldwide.
